blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2345653

EP2345653 - Morphinan compounds [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.11.2013
Database last updated on 12.07.2024
Most recent event   Tooltip20.02.2015Lapse of the patent in a contracting state
New state(s): MT		published on 25.03.2015  [2015/13]
Applicant(s)For all designated states
Concert Pharmaceuticals Inc.
99 Hayden Avenue, Suite 100
Lexington, MA 02421 / US
[2011/29]
Inventor(s)01 / Tung, Roger
99 Hayden Avenue, 500
Lexington Massachusetts 02421 / US
 [2011/38]
Former [2011/29]01 / Tung, Roger
99 Hayden Avenue 100
Lexington Massachusetts 02421 / US
Representative(s)Robertson, James Alexander
Marks & Clerk LLP
90 Long Acre
London WC2E 9RA / GB
[N/P]
Former [2012/52]Robertson, James Alexander
Marks & Clerk LLP
90 Long Acre
London
WC2E 9RA / GB
Former [2011/29]Robertson, James Alexander
Marks & Clerk LLP 90 Long Acre London
WC2E 9RA / GB
Application number, filing date11000763.030.04.2008
[2011/29]
Priority number, dateUS20070915130P01.05.2007         Original published format: US 915130 P
US20070916662P08.05.2007         Original published format: US 916662 P
US20070976044P28.09.2007         Original published format: US 976044 P
[2011/29]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2345653
Date:20.07.2011
Language:EN
[2011/29]
Type: B1 Patent specification 
No.:EP2345653
Date:26.12.2012
Language:EN
[2012/52]
Search report(s)(Supplementary) European search report - dispatched on:EP24.05.2011
ClassificationIPC:C07D471/08, C07B59/00, A61K31/439, A61P11/14
[2011/29]
CPC:
A61K31/195 (EP,US); A61K31/4709 (EP,US); A61K31/485 (EP,US);
A61K31/49 (EP,US); A61P11/04 (EP); A61P11/14 (EP);
A61P15/00 (EP); A61P15/10 (EP); A61P17/00 (EP);
A61P25/00 (EP); A61P25/04 (EP); A61P25/08 (EP);
A61P25/14 (EP); A61P25/18 (EP); A61P25/20 (EP);
A61P25/28 (EP); A61P25/30 (EP); A61P27/02 (EP);
A61P27/06 (EP); A61P27/16 (EP); A61P29/00 (EP);
A61P3/00 (EP); A61P3/02 (EP); A61P3/10 (EP);
A61P39/02 (EP); A61P43/00 (EP); A61P9/00 (EP);
A61P9/10 (EP); C07B59/002 (EP,US); C07D221/28 (EP,US);
C07D471/08 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2011/29]
TitleGerman:Morphinan Verbindungen[2011/29]
English:Morphinan compounds[2011/29]
French:Composés de morphine[2011/29]
Examination procedure24.08.2011Examination requested  [2011/41]
25.08.2011Amendment by applicant (claims and/or description)
29.06.2012Communication of intention to grant the patent
08.11.2012Fee for grant paid
08.11.2012Fee for publishing/printing paid
Parent application(s)   TooltipEP08747238.7  / EP2152709
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20080747238) is  06.07.2010
Opposition(s)27.09.2013No opposition filed within time limit [2013/49]
Fees paidRenewal fee
10.02.2011Renewal fee patent year 03
25.04.2011Renewal fee patent year 04
25.04.2012Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY26.12.2012
EE26.12.2012
LV26.12.2012
MC26.12.2012
MT26.12.2012
SI26.12.2012
BG26.03.2013
IS26.04.2013
[2015/13]
Former [2014/01]CY26.12.2012
EE26.12.2012
LV26.12.2012
MC26.12.2012
SI26.12.2012
BG26.03.2013
IS26.04.2013
Former [2013/52]CY26.12.2012
EE26.12.2012
LV26.12.2012
SI26.12.2012
BG26.03.2013
IS26.04.2013
Former [2013/35]EE26.12.2012
LV26.12.2012
SI26.12.2012
BG26.03.2013
IS26.04.2013
Former [2013/34]LV26.12.2012
SI26.12.2012
BG26.03.2013
IS26.04.2013
Former [2013/26]LV26.12.2012
SI26.12.2012
Former [2013/23]LV26.12.2012
Documents cited:Search[A]  - G. HEINKELE ET. AL., "Synthesis of [2H3]-dextromethorphan and its major urinary metabolites [2H3]-dextrorphan and [2H3]-dextrorphan-beta-glucoronide", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, (2002), vol. 45, pages 1153 - 1158, XP002490642 [A] 1-21 * whole article *

DOI:   http://dx.doi.org/10.1002/jlcr.640
 [A]  - T.H. EICHHOLD ET. AL., "Highly sensitive high-peformance liquid chromatographic-tandem mass spectrometric method for the analysis of dextromorphan in human plasma.", JOURNAL OF CHROMATOGRAPHY B, (1997), vol. 698, pages 147 - 154, XP002490644 [A] 1-21 * figure 1 *

DOI:   http://dx.doi.org/10.1016/S0378-4347(97)00308-3
 [A]  - G. HEINKELE ET. AL., "Synthesis of [2H]-labelled phase I metabolites using 1-[2H]-pyridinium hydrochloride.", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, (2005), vol. 48, pages 457 - 461, XP002490645 [A] 1-21 * figure 1 *

DOI:   http://dx.doi.org/10.1002/jlcr.941
 [AP]  - H. BÖLCSKEI ET. AL., "Synthesis of deuterated dextromethorphan derivatives.", ARKIVOK, (20080301), vol. 2008, no. iii, pages 182 - 193, XP002490643 [AP] 1-21 * page 183 - page 184; figure 1 *
by applicantUS4316888
 US4446140
 US4694010
 US4898860
 US5166207
 US5304121
 US5336980
 US5350756
 US5366980
 US5863927
 US5886026
 US6099562
 US6197830
 US6207164
 US2001044446
 US2002103109
 USRE38115E
 US6583152
 US2004087479
 US6803031
 US2005129783
 US2005203125
 US7014866
 US2006079502
 US2006094744
 US7114547
 US2007191411
    - MILLER, SC ET AL., ADDICT BIOL, (2005), vol. 10, no. 4, pages 325 - 7
    - NICHOLSON, KL ET AL., PSYCHOPHARMACOLOGY (BERL), (19990901), vol. 146, no. 1, pages 49 - 59
    - PENDER, ES ET AL., PEDIATR EMERG CARE, (1991), vol. 7, pages 163 - 7
    - ZAWERTAILO LA ET AL., J CLIN PSYCHOPHARMACOL, (199808), vol. 18, no. 4, pages 332 - 7
    - WADA E ET AL., SEIKAGAKU, (1994), vol. 66, page 15
    - GANES LZ ET AL., COMP BIOCHEM PHYSIOL A MOL INTEGR PHYSIOL, (1998), vol. 119, page 725
    - KIM HC ET AL., BIOORG MED CHEM LETT, (2001), vol. 11, page 1651
    - NEWMAN AH ET AL., J MED CHEM, (1992), vol. 35, page 4135
    - FREIREICH ET AL., CANCER CHEMOTHER. REP, (1966), vol. 50, page 219
    - Scientific Tables, Geigy Pharmaceuticals, ARDSLEY, (1970), page 537
    - SIEGEL BW; SREEKRISHNA K; BARON BM, "Binding of the radiolabeled glycine site antagonist [3H]MDS105,519 to homomeric NMDA-NRIa receptors", EUR J PHARMACOL., (1996), vol. 312, no. 3, pages 357 - 365
    - GOLDMAN ME; JACOBSON AE; RICE KC; PAUL SM, "Differentiation of [.H] phencyclidine and (+)-[.H]SKF-10047 binding sites in rat cerebral cortex", FEBS LETT., (1985), vol. 190, pages 333 - 336
    - GANAPATHY ME; PRASAD PD; HUANG W; SETH P; LEIBACH FH; GANAPATHY V, "Molecular and ligand-binding characterization of the s-receptor in the Jurkat human T lymphocyte cell line", J PHARMACOL EXP THER., (1999), vol. 289, pages 251 - 260
 US19620609166
 US20040609760
 US20070915130
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.